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Abstract 
Background: Mood stabilizers like lithium and anticonvulsants are used in bipolar and related psychotic disorders. 
There is a lack of knowledge of the relationship of these medications and cognition in the psychosis spectrum. We 
studied the association between serum concentration of mood stabilizers and cognitive performance in a well-char-
acterized sample of bipolar and schizophrenia spectrum disorders.
Methods: Serum concentrations of valproate, lamotrigine, and lithium were analyzed for associations to perfor-
mance on neuropsychological tests in six cognitive domains in individuals with bipolar disorder (n = 167) and in a 
combined sample of individuals with bipolar or schizophrenia spectrum disorders (n = 217). Linear regression with 
adjustments for gender, age, and symptom levels of depression, mania, and psychosis were applied for the associa-
tion analyses.
Results: There were negative associations between serum levels of valproate and short term delayed recall (bipolar: 
p = 0.043; combined: p = 0.044) and working memory (bipolar: p = 0.043). A positive association was suggested 
between serum level of lithium and working memory (bipolar: p = 0.039). There were no other significant relation-
ships between serum levels of valproate, lamotrigine, or lithium and neuropsychological test performance in neither 
the bipolar disorder nor the combined group.
Conclusions: Serum levels of mood stabilizers were unrelated to cognitive performance in most domains, indicating 
that higher dose does not lead to broader cognitive impairments in bipolar and related psychotic disorder patients. 
However, worsened memory with increasing levels of valproate suggests cautious dosing of anticonvulsants, while 
increasing lithium level seems to be associated with improved memory. The findings should be interpreted with cau-
tion due to the explorative, naturalistic design.
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Background
Cognitive impairment is well documented in bipolar 
and related psychosis spectrum disorders (Bourne et  al. 
2013; Vaskinn et al. 2014). Both decreased and superior 
cognitive abilities seem to be associated with contract-
ing bipolar disorder (Bora 2015), while history of psy-
chosis (Simonsen et  al. 2011), duration of illness, mood 
episodes, and hospitalizations (Cardoso et al. 2015) have 
been associated with differences in cognitive perfor-
mance after disease onset. Cognitive domains typically 
affected include memory, attention, processing speed, 
and executive functioning (Bourne et al. 2013), with the 
impairments having a substantial impact on social and 
occupational outcome (Baune and Malhi 2015). The need 
to address the cognitive aspect in treatment is obvious; 
however, research on cognitive implications of standard 
medication in bipolar and related disorders is sparse.
Lithium and the anticonvulsant agents valproate and 
lamotrigine are classical mood stabilizers used in the 
treatment of bipolar disorder. They are also used as 
adjunctives in schizophrenia in attempts to optimize 
treatment effect (Citrome 2009). Lithium has been found 
to negatively influence verbal memory and psychomotor 
speed; however, there are as well indications of brain pro-
tective effects, suggesting cognitive benefits. Valproate 
has been associated with impaired cognitive functioning 
in several domains, while studies of lamotrigine indicate 
less negative influences, even advantageous effects for 
certain domains such as memory and verbal fluency have 
been suggested (see Dias et  al. 2012 for an overview of 
mood stabilizers and cognition).
One central factor for assessing cognitive perfor-
mance during treatment with mood stabilizers is the 
actual level of drug exposure. This is shown in animal 
studies (Honarmand et  al. 2014), human dementia stud-
ies (Leyhe et  al. 2009), as well as in epilepsy samples. In 
psychiatric samples, there are some preliminary find-
ings suggesting effects of serum level of lithium; both 
worsened verbal learning, memory, and executive func-
tion (Bora et  al. 2007; Squire et  al. 1980) and improved 
short term memory (Squire et  al. 1980) associated with 
higher serum levels are suggested. However, gener-
ally, there is no solid evidence supporting that lithium 
enhances memory in any meaningful fashion. Relations 
between serum levels of valproate and cognitive perfor-
mance have been studied in patients with epilepsy; these 
studies indicate worsened cognition or no association with 
cognitive performance with higher serum concentrations 
(Brouwer et al. 1992; Gallassi et al. 1990; Jakovljevic et al. 
2008; Prevey et  al. 1996; Trimble and Thompson 1984). 
For lamotrigine, there is a lack of data of the relationship 
between serum concentration and cognitive performance 
both in epilepsy and psychosis spectrum disorders.
In the present study, we investigated the relationships 
between serum concentrations of mood stabilizers and 
cognitive functioning in bipolar and related psychotic 
disorders. This is done in a large and well-characterized 
sample, enabling adjustments for several confounders. 
Using serum levels instead of dosage, the regular biases 
due to adherence issues and interindividual variations in 
pharmacokinetics are avoided. Moreover, blood sampling 
was performed the same morning as the neuropsycho-
logical battery, enabling an almost direct comparison. 
Due to the sparse literature, the analyses were basically 
explorative, although it was possible to make a few expec-
tations. For valproate, we expected no associations or 
tentatively worsened cognitive performance with increas-
ing serum levels. For lithium, we expected no associa-
tions or tentatively worsened verbal learning, memory, 
and executive function and improved short term memory 




Patients were included through the ongoing themati-
cally organized psychosis (TOP) study carried out by the 
University Hospitals of Oslo, Norway. The TOP study is 
a multicenter study focusing on neurobiological, genetic, 
psychologic, and environmental mechanisms behind psy-
chosis spectrum disorders. Patients are recruited through 
referrals from in- and out-patient mental health clin-
ics with a catchment area of basically the city of Oslo. 
General inclusion criteria for the TOP study are being 
registered in the psychiatric services of any one of the 
participating hospitals, age 18–65  years, meeting the 
diagnostic and statistical manual of mental disorders 
(DSM)-IV (American Psychiatric Association 2000) cri-
teria for bipolar or schizophrenia spectrum disorders, 
and being willing and able to give written, informed con-
sent to participation. General exclusion criteria are a his-
tory of moderate or severe head injury, serious somatic 
illness, neurological disorder, and mental retardation (see 
also Birkenaes et al. 2007 for a broader description).
Included in the current analyses were consecutively 
referred patients from 2003 to 2014 with a DSM-IV bipo-
lar disorders diagnosis, in the following termed “bipolar 
disorder” (BD, N  =  167), or a schizophrenia and other 
psychotic disorders diagnosis, in the following termed 
“schizophrenia” (SCZ, N = 50), with neuropsychological 
testing and concurrent measurements of serum levels of 
lamotrigine or valproate recorded as primary anticonvul-
sant drug, or concurrent measurements of serum levels 
of lithium. Selection of anticonvulsants was based on the 
prescription frequency in the sample. Table 1 shows the 
sample characteristics.
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Clinical assessments
Inclusion and diagnostic interviews were done by trained 
medical doctors and psychologists using The Struc-
tured Clinical Interview for DSM-IV Axis I Disorders, 
SCID 1 (First et al. 1995). Inter-rater reliability was good, 
with an overall kappa score of 0.77 (95% C.I 0.60–0.94). 
The inventory of depressive symptomatology-clinician 
rated (IDS-C) (Rush et  al. 1996), Young mania rating 
scale (YMRS) (Young et al. 1978), the structured clinical 
interview for the positive and negative syndrome scale 
(SCI-PANSS) (Kay et  al. 1987), and global assessment 
of functioning, symptom scale (GAF-S) (Pedersen et  al. 
2007) were used for symptom assessments (Table 1).
We recorded dosage of antipsychotics and antide-
pressants for the purpose of statistical adjustments. To 
combine different drugs within these categories, we 
calculated the ratio of the reported dose to the defined 
daily dose of the drug (DDD) (ATC/DDD Index 2016, 
WHO), using the sum of the ratios if a subject used more 
than one drug from a category. If a subject did not use 
any medication within a category, the value was set to 
zero. Information about pharmacological treatment was 
obtained from interviews and medical records. See also 
previous papers by Steen et al. (2011, 2015).
Neuropsychological assessments
Within 2  weeks after clinical assessments, a 3-h neu-
ropsychological test battery was administered in a fixed 
order with 2 refreshment breaks (Simonsen et al. 2011). 
Clinical psychologists with training in standardized neu-
ropsychological testing administered the tests, super-
vised by a professor in neuropsychology, who also was 
in charge of the quality control. Test scoring was initially 
calibrated across investigators on the verbal tests from 
the Wechsler abbreviated scale of intelligence (WASI) 
(Wechsler 2007) in order to assure a common scoring 
technique. Six neuropsychological domains were selected 
for analyses. Verbal learning was measured by the Cali-
fornia verbal learning test (CVLT) subscore Total A1–5 
(Delis et  al. 2004). Verbal memory was divided into 
“immediate recall”, “short term delayed recall”, and “long 
term delayed recall”. Immediate recall was assessed using 
the logical memory test subscore immediate recall from 
the Wechsler memory scale (Wechsler et al. 2008). Short 
term delayed recall was assessed using the CVLT sub-
score short delay free recall. Long term delayed recall was 
assessed using the CVLT subscore long delay free recall, 
and the logical memory test subscore delayed recall. 
Attention was assessed using the digit span test for-
ward from the Wechsler adult intelligence scale (WAIS) 
(Wechsler 2003). Working memory was assessed using 
the digit span test backward from WAIS. Executive func‑
tioning was assessed using tests from the Delis–Kaplan 
executive function scale (D-KEFS), more specifically 
the verbal fluency test, with subscore measures of pho-
netic fluency and semantic fluency, and the interference 
control test subscore color-word inhibition and color-
word inhibition/switching (Delis et  al. 2005). Processing 
speed was assessed using the digit symbol coding test 
from WAIS, and the interference control test subscore 
Table 1 Demographic data, diagnosis, and  psychophar-
macological treatment
BD bipolar disorder, IDS inventory of depressive symptomatology, IQR 
interquartile range, N number, NOS not otherwise specified, SCI-PANSS 
structured clinical interview for the positive and negative syndrome scale, SCZ 
schizophrenia and other psychotic disorders, YMRS Young mania rating scale
a DSM-IV (American Psychiatric Association 2000)
b Duration of treatment (months, median [IQR]): 4.0 (13.6); participants with BD: 
N = 82 (lamotrigine), N = 43 (valproate)
c Duration of treatment (months, median [IQR]): 8.0 (64.3); participants with BD: 
N = 52
d Of these N = 5 used lamotrigine + valproate, N = 4 used valproate + lithium, 
and N = 8 used lamotrigine + lithium
e Defined as hypnotics, anxiolytics, or sedatives
Median IQR
Age (years) 33.0 17.0
IDS, total score 15.0 18.0
YMRS, total score 2.0 8.0
SCI-PANSS, total score 46.0 17.0
N %
Total number of participants 217 100
Number of males 89 41.0
Diagnosis
 Schizophrenia and other psychotic disordersa 50 23.0
  Schizophrenia 21 9.7
  Schizophreniform disorder 2 0.9
  Schizoaffective disorder 17 7.8
  Delusional disorder 1 0.5
  Brief psychotic disorder 1 0.5
  Psychotic disorder NOS 8 3.7
 Bipolar disordersa 167 77.0
  Bipolar I disorder 117 53.9
  Bipolar II disorder 42 19.4
  Bipolar disorder NOS 8 3.7
Main anticonvulsant drugb
 Lamotrigine 109 50.2
 Valproate 62 28.6
Lithiumc 58 26.7
More than one mood stabilizerd 17 7.8
Other psychotropic drugs
  Use of other anticonvulsant drugs 11 5.1
  Use of antipsychotics 128 59.0
  Use of antidepressants 86 39.6
  Use of sedativese 35 16.1
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color-word color-naming from D-KEFS. Table  2 shows 
the neuropsychological scores. Raw-scores were used 
across cognitive domains.
Serum concentration measurements of anticonvulsant 
drugs and lithium
Blood was drawn from the antecubital vein in the morn-
ing the same day as the neuropsychological testing took 
place. The patients met fasting for blood sampling with-
out taking their morning medication. Thus, blood for 
serum levels measurements were collected on average 12 
or 24 h after last dose according to standard laboratory 
requirements. After blood sampling, the patients took 
their morning medication, had a light breakfast and a 
brief physical examination. Then the neuropsychological 
testing was done with a standard sequence of tests start-
ing on average 1 h after blood sampling. The laboratories 
and breakfast room were located close to each other in 
the same building. Serum concentrations of lamotrig-
ine were analyzed with a liquid chromatography–mass 
spectrometry (LC–MS) method developed in our labo-
ratory and described in detail elsewhere (Reimers et  al. 
2005). Serum concentrations of valproate and lithium 
were analyzed by means of commercially available kits 
using a Cobas Integra 400 plus system (Roche Diagnos-
tics, Rotkreutz, Switzerland). Table  2 shows the serum 
concentrations.
Ethics
The study was carried out in accordance with the Dec-
laration of Helsinki. After complete description of the 
study to the subjects, written informed consent was 
obtained. The Regional Ethics Committee South-East and 
The Norwegian Data Inspectorate approved the study. 
The biobank was approved by The Norwegian Directo-
rate of Health.
Statistical analysis
Neuropsychological test scores from the six domains were 
tested for associations with serum concentrations of lam-
otrigine, valproate, and lithium using linear regressions. 
This was done for all three compounds in the BD sample 
and in the combined BD and SCZ sample, respectively. 
Neuropsychological test scores were set as dependent 
variables. For the BD sample, gender, age, serum concen-
tration of the medication, and total scores of IDS-C and 
YMRS (lamotrigine and lithium), or GAF-S (valproate, 
due to smaller sample) were set as independent variables. 
For the combined BD and SCZ sample, gender, age, IDS-
C, YMRS, SCI-PANSS, and serum concentration were set 
as independent variables. The final basic regression mod-
els were decided with a backwards elimination procedure 
using a significance threshold of ≥0.1 for elimination of 
excessive independent variables. The dependent variables 
were transformed using logarithmic, squared, or recipro-
cal transformation when required. Based on our previous 
findings of associations between serum levels of antide-
pressants and antipsychotics and cognitive performance 
(Steen et al. 2015, 2016), we also did extended statistical 
analyses in the combined sample by including dosage of 
antidepressants and antipsychotics, respectively, as inde-
pendent variables. For descriptive purposes, we did asso-
ciation analyses between the cognitive measures, and 
between daily doses and serum levels of the mood stabi-
lizers, using Spearman’s rho. For testing between group 
differences of serum concentrations, we used Mann–
Whitney U test.
Table 2 Serum concentration of  mood stabilizers, 
and neuropsychological test scores
SCZ schizophrenia and other psychotic disorders, BD bipolar disorder, IQR 
interquartile range, CVLT California verbal learning test, CW color-word
a There were no significant differences in serum concentrations of mood 
stabilizers between BD and SCZ
b Scores were missing for 6% of subjects in the SCZ group
c Scores were missing for 8% of subjects in the SCZ group
BD SCZ
Median IQR Median IQR
Serum concentrations of mood stabilizersa
 Lamotrigine (µmol/L) 10.4 13.1 8.4 10.4
 Valproate (µmol/L) 304 336 386 428
 Lithium (mmol/L) 0.58 0.27 0.60 0.46
Neuropsychological test scores
 Verbal learning
  CVLT Total A1-5 56.0 15.0 48.0 15.3
 Verbal memory—immediate recall
  Logical memory test immediate 
recall
24.0 10.0 20.5 10.5
 Verbal memory—short term delayed recall
  CVLT short delay free recall 13.0 5.0 11.0 5.5
 Verbal memory—long term delayed recall
  CVLT long delay free recall 13.0 4.0 12.0 5.3
  Logical memory test delayed recall 22.0 11.0 16.0 11.5
 Attention
  Digit span test forwards 6.0 2.0 6.0 2.0
 Working memory
  Digit span test backwards 4.0 1.0 4.0 2.0
 Executive function
  Verbal fluency test letterb 43.0 18.3 33.0 25.0
  Verbal fluency test categoryc 44.0 12.0 35.5 16.3
  CW 3 inhibition 56.0 18.3 64.0 28.3
  CW 4 inhibition/switching 60.0 18.0 65.0 29.5
 Processing/psychomotor speed
  Digit symbol coding test 67.0 21.0 53.0 24.3
  CW Stroop (color naming) 31.0 9.0 38.0 13.0
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Results
Cognitive test scores correlated significantly across 
the cognitive tests in the total sample (Spearman’s 
rho = 0.15–0.90 [absolute values], p = <0.001 to 0.031). 
Daily drug doses and serum concentrations correlated 
significantly for each drug (lamotrigine: Spearman’s 
rho = 0.77, p < 0.001; valproate: Spearman’s rho = 0.54, 
p < 0.001; lithium: Spearman’s rho = 0.34, p = 0.009).
Associations between serum concentrations 
of anticonvulsants and cognitive performance
BD sample
Significant associations in  the BD sample Negative 
associations were suggested between serum concentra-
tion of valproate and working memory and short term 
delayed recall. This was shown by significant main effects 
in the regressions for valproate (digit span test backward 
[β = −0.28, p = 0.043]; CVLT subscore short delay free 
recall [β = −0.30, p = 0.043]) (Fig. 1a, b).
Combined sample
Significant and  trend‑level significant associations in  the 
combined sample Negative associations were suggested 
between serum concentration of valproate and short 
term delayed recall, long term delayed recall, and work-
ing memory, and between serum concentrations of lamo-
trigine and working memory. This was shown by a sig-
nificant main effect in a regression for valproate (CVLT 
subscore short delay free recall [standardized coefficient 
[β] = −0.26, p = 0.044]), and trend-level significant main 
effects in regressions for valproate (CVLT subscore long 
delay free recall [β = −0.24, p = 0.055, criteria of normally 
distributed residuals violated]; digit span test backward 
[β = −0.24, p = 0.058]) and lamotrigine (digit span test 
backward [β = −0.18, p = 0.058, before backward elimi-
nation: β = −0.19, p = 0.046]).
There were no other associations indicated between 
serum concentrations of lamotrigine or valproate and 
neuropsychological test scores in the BD or the combined 
sample in any of the tested cognitive domains, as shown 
by no significant main effects of the serum concentra-
tions of lamotrigine or valproate in the linear regressions.
Associations between serum concentration of lithium 
and cognitive performance
BD sample
Significant and  trend‑level significant associations in  the 
BD sample Data were suggestive of positive associa-
tions between serum concentration of lithium and work-
ing memory and attention as shown by the main effects 
in the regressions for lithium (digit span test backward 
[β  =  0.29, p  =  0.039, Fig.  1c]; digit span test forward 
[β = 0.24, p = 0.087]).
Combined sample
Trend‑level significant associations in the combined sam‑
ple Data were slightly suggestive of positive associations 
between serum concentration of lithium and attention 
and working memory as shown by the main effects in 
the regressions for lithium (digit span test forward [non-
significant after backwards elimination procedure, before 
backward elimination: β  =  0.27, p  =  0.056]; digit span 
test backward [β = 0.23, p = 0.081, non-significant after 
removing an observation with Cook’s distance = 0.40 and 
centered leverage value = 0.20]).
There were no other associations indicated between 
serum concentrations of lithium and neuropsychological 












































































Serum concentraon of mood stabilizer
Fig. 1 Scatter plots of the serum concentrations (x-axis) of valproate (µmol/L) (a, b) and lithium (mmol/L) (c) and neuropsychological test scores 
(y-axis) of digit span test backwards (a, c), and California verbal learning test (CVLT) short delay free recall (b) in the bipolar disorder sample
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the tested cognitive domains, as shown by no significant 
main effects of the serum concentrations of lithium in the 
linear regressions.
Discussion
The main finding in the present study is no association 
between serum levels of lamotrigine, valproate, or lith-
ium and performance on most neuropsychological tests 
from a broad test battery in individuals with bipolar and 
schizophrenia spectrum disorders. Significant associa-
tions suggested worsened short term delayed recall and 
working memory with increasing valproate concentra-
tion, and better working memory with increasing lithium 
concentration in BD. Findings in the combined BD and 
SCZ sample corresponded to those in BD for valproate.
Except from potentially negative effects of anticonvul-
sants on memory, the present findings indicate that the 
risk of broader cognitive side effects due to increasing 
the dosage of lamotrigine, valproate, or lithium is small. 
Correspondingly, there neither seems to be clinically sig-
nificant cognitive benefits by adjusting the dosage. This 
is in line with previous studies showing that neuropsy-
chological test performance is mainly not associated with 
the drug serum concentrations of valproate and lithium 
(Bora et al. 2007; Prevey et al. 1996). However, there are 
a few indications in the scientific literature of effects of 
the level of exposure, and the present data suggesting 
negative associations between memory and serum level 
of valproate are in line with such reports (Jakovljevic 
et al. 2008; Prevey et al. 1996). Moreover, although nega-
tive associations between serum lithium and memory 
also have been reported (Bora et  al. 2007), the present 
positive association between serum lithium and working 
memory is in line with a previously indicated association 
between serum lithium and short term memory in cor-
relation analyses in the study by Squire et al. (1980). As 
discussed by Cowan (2008), working memory and short 
term memory are regarded as closely associated abilities.
The previously suggested worsened memory and exec-
utive function with increasing lithium exposure (Bora 
et al. 2007; Squire et al. 1980) were not replicated in the 
present study. This may depend on methodological dif-
ferences. In the study by Bora et  al. (2007), the sample 
consisted of euthymic bipolar I disorder patients, and 
with an unexplained criterion of minimum 2 manic epi-
sodes to be included. Moreover, there was no correction 
of significance level for multiple testing, and the p value 
was  >0.035 for the reported correlation with memory. 
Thus, in addition to an unusual inclusion criterion, the 
reported negative association seems prone to type 1 
error given the number of analyses. In the present study, 
we used a broader clinical sample, and with diagnostics 
following the DSM-IV criteria. In this way, the results 
seem more easily generalizable to everyday clinical prac-
tice. Similarly, in the cross-over study by Squire et  al. 
(1980), the sample was small (N = 16), and most of the 
participants had a diagnosis of alcohol abuse or depend-
ency. These factors are in contrast to the present study 
with a several-fold larger subsample using lithium, ena-
bling adjustments for important variables and reducing 
the risk of spurious associations, and without a similar 
impact from substance abuse and dependency. Impor-
tantly, alcohol dependency has been associated with cog-
nitive decrements (Bernardin et al. 2014).
The processing of data was performed without taking 
into account reference serum values of the drugs. This 
was done as there is no a priori reason to believe that 
the biological effects on cognitive performance are con-
fined to the therapeutic reference intervals for treating 
affective symptoms. Moreover, we wanted to gain knowl-
edge of the potential association between serum levels 
of mood stabilizers and cognitive performance irrespec-
tive of the treatment effect. In line with this, we adjusted 
for symptom load in the statistical analyses. However, 
it should be noted that the median values of the serum 
concentrations (Table 2) of valproate in the BD group and 
of lamotrigine in both the BD and the SCZ groups were 
below the recommended reference intervals (Hiemke 
et al. 2011). Although Fig. 1 indicates a fairly good spread 
of data, low serum concentrations in these groups might 
have limited the ability to uncover significant associa-
tions, and possibly also the relevance to a broader popu-
lation receiving mood stabilizers.
The strength of the study includes the use of serum lev-
els as independent variables. This helps prevent biases at 
the level of the neuropsychological test administrator, 
and eliminates uncertainties of medication adherence 
and differences in pharmacokinetics. Moreover, by blood 
sampling being performed the same morning as the neu-
ropsychological testing, an accurate measure of the rel-
evant drug level was obtained (Steen et  al. 2015). The 
neuropsychological testers were calibrated and supervised, 
assuring the quality of the dependent variables. Moreover, 
the sample is large compared to previous studies, enabling 
adjustments for several confounders. Due to the last cou-
ple of decades’ generation of knowledge of the cognitive 
impairments in psychosis spectrum disorders (Bourne 
et al. 2013; Kahn and Keefe 2013), a detailed analysis of the 
effects of the commonly used psychotropic drugs is per-
tinent. We have previously shown relationships between 
serum levels of antidepressants and antipsychotics and 
cognitive performance (Steen et  al. 2015, 2016), and the 
present findings complement the cognitive aspects of 
standard medication in bipolar and related disorders.
Some limitations have to be considered. There are few 
previous studies on the topic, making the analyses largely 
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explorative and the indicated associations preliminary. 
Especially, there are minimal former data of psychiat-
ric samples. Due to the cognitive impairments in these 
patients groups, we did not adjust the significance level, 
despite the number of tests, to reduce the risk of over-
looking adverse cognitive effects (type II errors). How-
ever, with the open naturalistic design, non-randomized 
treatment and lack of control group, there is a possibility 
of missing associations, as the study is vulnerable to con-
founders, including use of co-medications. However, we 
were able to adjust for several important variables due to 
the considerable sample size, including use of antidepres-
sants and antipsychotics. A significant impact from seda-
tives is unlikely, as only 16.1% of the participants were 
registered with such medication, of which about half were 
short-acting hypnotics taken in the evening. Moreover, 
the study did find negative associations between cogni-
tion and drug-levels, and the usual concern of naturalistic 
studies of higher drug doses used for increased severity 
of condition (Bolstad et al. 2011; for a discussion, see Ho 
et  al. 2007) would rather strengthen negative associa-
tions. In addition to specific analyses of the BD sample, 
we analyzed the larger combined sample with the poten-
tial of discovering weaker associations; however, there 
were fewer significant findings in the combined sam-
ple, possibly due to larger heterogeneity. Heterogeneity 
might also have influenced the results in the BD sample, 
which included the complete DSM-IV bipolar disor-
ders category. However, given the current sample size, 
it is unlikely that clinical meaningful associations would 
not have been detected. We did not perform specific 
analyses of SCZ due to the smaller sample size prevent-
ing appropriate statistical adjustments within each drug 
group. Moreover, it should be noted that lack of analyses 
of subjective cognitive complaints, might limit the gen-
eralizability of the findings to daily life. Lastly, the rather 
young age of the patients in the present sample should be 
noted. We included age as an independent variable in the 
analyses; however, specific analyses of older age groups in 
a larger sample would have been preferable based on pre-
vious suggested effects (Forester et al. 2009).
In the present study, we investigated the serum levels 
of commonly used mood stabilizers in relation to cog-
nitive performance in six cognitive domains in a well-
characterized sample of BD and SCZ. The main finding 
was no association between serum level of lamotrigine, 
valproate, or lithium and cognitive performance in most 
domains. A negative association for valproate and mem-
ory was indicated, and deserves further investigation in 
larger samples. The data were suggestive of a positive 
association between lithium level and working memory; 
however, the finding was too weak to indicate signifi-
cant clinical implications. The present study of serum 
levels of mood stabilizers and cognition is one of the 
first studies in a considerable large sample of psychosis 
spectrum patients, and although in need of replication, 
gives reason to believe that lamotrigine, valproate, and 
lithium can be administered across the dosage ranges 
without broad cognitive adverse effects. However, 
higher doses of anticonvulsants might negatively affect 
memory.
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